Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on World Healthcare Report.
Press releases published on May 28, 2025

Nyxoah to Present at the Jefferies Global Healthcare Conference
Nyxoah to Present at the Jefferies Global Healthcare Conference Mont-Saint-Guibert, Belgium – May 28, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops …

Nyxoah Participera à la Jefferies Global Healthcare Conference
Nyxoah Participera à la Jefferies Global Healthcare Conference Mont-Saint-Guibert, Belgique – 28 mai 2025, 22h30 CET / 16h30 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société ») une société de technologie médicale développant …

CVRx to Present at the William Blair 45th Annual Growth Stock Conference
MINNEAPOLIS, May 28, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular …

Gentherm Announces Participation in Upcoming Second Quarter 2025 Investor Conferences
NOVI, Mich., May 28, 2025 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM), a global market leader of innovative thermal management and pneumatic comfort technologies, today announced that it is scheduled to participate in the following upcoming investor events …

Healios K.K. to Present at the 2025 Jefferies Global Healthcare Conference
NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- HEALIOS K.K. (“Healios”) is pleased to announce that Richard Kincaid, Chief Financial Officer, will present at the 2025 Jefferies Global Healthcare Conference in New York City as follows: Date …

CoreMap, Inc. Receives U.S. FDA Investigational Device Exemption (IDE) Approval for INvENI Map-Guided AF Ablation Study
BURLINGTON, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- CoreMap today announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to extend the INvENI clinical study into the U.S. This study is …

Supernus Announces Paragraph IV ANDA Filings for Qelbree®
ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that …

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference
ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that …

Pulmonx to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
REDWOOD CITY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the company will be presenting at the Goldman Sachs …

Cytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare Conference
FREMONT, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference in …

ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing
Financing led by SR One and includes participation from new and existing investors, including Point72, Viking Global Investors, Venrock Healthcare Capital Partners, New Enterprise Associates (NEA), Nextech, Vivo Capital, and NEXTBio Capital Pro forma cash …

ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC
Broad and deep PSA responses achieved, with 59% PSA50 response rate (confirmed rate of 47%, and one additional response pending confirmation) and 24% PSA90 response rate (all confirmed) in patients with mCRPC PSA responses were observed across all …

Sanuwave Health Appoints Greg Bazar to Board of Directors
EDEN PRAIRIE, Minn., May 28, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (Nasdaq:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the addition of Greg Bazar to its Board …

Sana Biotechnology to Present at June 2025 Investor Conferences
SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June. …

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
DALLAS, May 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the …

argenx Announces Results of Annual General Meeting of Shareholders
May 28, 2025 – 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext …

Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress
PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today …

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and …

Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102
Natural history data analysis established patients ≥ six years of age are in developmental plateau, with a ~0% likelihood of gaining/regaining developmental milestones across the core functional domains of Rett syndrome Written alignment from FDA supports …

Disc Medicine to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious …